{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T11:33:02Z","timestamp":1793791982776,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan","award":["#16729791, #19111599"],"award-info":[{"award-number":["#16729791, #19111599"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>We reported that the production of BAFF (B cell-activating factor) and IL-6, both of which are involved in survival and differentiation of B cells, is dysregulated in monocytes of patients with primary Sj\u00f6gren\u2019s syndrome (pSS). In this study, we investigate the relationship between possible aberrations of pSS monocytes and clinical features of pSS patients and the contribution of monocytes to B cell activation, a mechanism involved in the pathogenesis of pSS.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Expression of BAFF-receptor (BR3) on peripheral monocytes from patients with pSS (<jats:italic>n<\/jats:italic>\u2009=\u200967) and healthy controls (HC: <jats:italic>n<\/jats:italic>\u2009=\u200937) was analyzed by FACS. Peripheral monocytes were stimulated with BAFF, and IL-6 production by the cells was measured by ELISA. Peripheral B cells were cultured with BAFF-stimulated monocytes in the presence or absence of anti-IL-6 receptor antibody, and IgG production by the cells was measured by ELISA. Patients\u2019 serological data were collected from their clinical records. Patients\u2019 disease activity was quantified based on their EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI) scores.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The proportion of peripheral BR3-positive monocytes (BR3<jats:sup>+<\/jats:sup>\/CD14<jats:sup>+<\/jats:sup>) was significantly increased in pSS patients compared to HC. Moreover, IL-6 production by BAFF-stimulated monocytes was remarkably higher than HC and was significantly correlated with BR3<jats:sup>+<\/jats:sup>\/CD14<jats:sup>+<\/jats:sup> ratios of patients. In addition, BR3 expression on pSS monocytes was elevated in anti-Ro\/SSA and\/or anti-La\/SSB positive compared to negative patients. Remarkably, BR3 expression on peripheral monocytes was positively and significantly correlated with patients\u2019 serum IgG and IgM levels and ESSDAI scores. Moreover, the amount of IgG produced by B cells was markedly higher in pSS patients compared to HC when the cells were co-cultured with BAFF-stimulated autologous monocytes in vitro. Notably, addition of anti-IL-6 receptor antibody into the co-culture system led to inhibition of IgG production by B cells.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our data suggest that elevated BR3 expression in monocytes is associated with clinical features in pSS patients and that enhanced production of IL-6 by BAFF-stimulated monocytes plays a part in the overproduction of IgG by B cells in pSS. These results suggest that BAFF signaling pathways through BR3 in monocytes are possible therapeutic targets for pSS.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13075-020-02249-1","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T11:03:07Z","timestamp":1592910187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Elevated expression of BAFF receptor, BR3, on monocytes correlates with B cell activation and clinical features of patients with primary Sj\u00f6gren\u2019s syndrome"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6491-267X","authenticated-orcid":false,"given":"Keiko","family":"Yoshimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"2249_CR1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1568-9972(03)00102-2","volume":"3","author":"Y Masaki","year":"2004","unstructured":"Masaki Y, Sugai S. Lymphoproliferative disorders in Sjogren\u2019s syndrome. Autoimmun Rev. 2004;3:175\u201382.","journal-title":"Autoimmun Rev"},{"key":"2249_CR2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.berh.2004.03.007","volume":"18","author":"J Sheldon","year":"2004","unstructured":"Sheldon J. Laboratory testing in autoimmune rheumatic diseases. Best Pract Res Clin Rheumatol. 2004;18:249\u201369.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2249_CR3","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.4049\/jimmunol.167.7.3610","volume":"167","author":"JO Bohnhorst","year":"2001","unstructured":"Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren\u2019s syndrome. J Immunol. 2001;167:3610\u20138.","journal-title":"J Immunol"},{"key":"2249_CR4","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/ard.2008.096172","volume":"68","author":"A Binard","year":"2009","unstructured":"Binard A, Le Pottier L, Devauchelle-Pensec V, Saraux A, Youinou P, Pers JO. Is the blood B-cell subset profile diagnostic for Sjogren\u2019s syndrome? Ann Rheum Dis. 2009;68:1447\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2249_CR5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.jaci.2016.01.024","volume":"137","author":"M Mingueneau","year":"2016","unstructured":"Mingueneau M, Boudaoud S, Haskett S, Reynolds TL, Nocturne G, Norton E, et al. Cytometry by time-of-flight immunophenotyping identifies a blood Sj\u00f6gren\u2019s signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol. 2016;137(6):1809\u201321.","journal-title":"J Allergy Clin Immunol"},{"key":"2249_CR6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.clim.2017.10.008","volume":"187","author":"E Ishioka-Takei","year":"2018","unstructured":"Ishioka-Takei E, Yoshimoto K, Suzuki K, Nishikawa A, Yasuoka H, Yamaoka K, et al. Increased proportion of a CD38highIgD+ B cell subset in peripheral blood is associated with clinical and immunological features in patients with primary Sj\u00f6gren\u2019s syndrome. Clin Immunol. 2018;187:85\u201391.","journal-title":"Clin Immunol"},{"key":"2249_CR7","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","volume":"189","author":"P Schneider","year":"1999","unstructured":"Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189:1747\u201356.","journal-title":"J Exp Med"},{"key":"2249_CR8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","volume":"404","author":"JA Gross","year":"2000","unstructured":"Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995\u20139.","journal-title":"Nature."},{"key":"2249_CR9","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1126\/science.1061965","volume":"293","author":"JS Thompson","year":"2001","unstructured":"Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293:2108\u201311.","journal-title":"Science."},{"key":"2249_CR10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/76889","volume":"1","author":"M Yan","year":"2000","unstructured":"Yan M, Marsters SA, Grewal IS, Wang H, Ashkenazi A, Dixit VM. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol. 2000;1:37\u201341.","journal-title":"Nat Immunol"},{"key":"2249_CR11","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","volume":"285","author":"PA Moore","year":"1999","unstructured":"Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260\u20133.","journal-title":"Science."},{"key":"2249_CR12","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/jlb.65.5.680","volume":"65","author":"HB Shu","year":"1999","unstructured":"Shu HB, Hu WH, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol. 1999;65:680\u20133.","journal-title":"J Leukoc Biol"},{"key":"2249_CR13","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1515\/BC.1999.186","volume":"380","author":"C Tribouley","year":"1999","unstructured":"Tribouley C, Wallroth M, Chan V, Paliard X, Fang E, Lamson G. Characterization of a new member of the TNF family expressed on antigen presenting cells. Biol Chem. 1999;380:1443\u20137.","journal-title":"Biol Chem"},{"key":"2249_CR14","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/intimm\/dxl053","volume":"18","author":"K Yoshimoto","year":"2006","unstructured":"Yoshimoto K, Takahashi Y, Ogasawara M, Setoyama Y, Suzuki K, Tsuzaka K, et al. Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line. Loucy Int Immunol. 2006;18:1189\u201396.","journal-title":"Loucy Int Immunol"},{"key":"2249_CR15","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1126\/science.1061964","volume":"293","author":"B Schiemann","year":"2001","unstructured":"Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293:2111\u20134.","journal-title":"Science."},{"issue":"5","key":"2249_CR16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","volume":"72","author":"Z Brkic","year":"2013","unstructured":"Brkic Z, Maria NI, van Helden-Meeuwsen CG, van de Merwe JP, van Daele PL, Dalm VA. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren\u2019s syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis. 2013;72(5):728\u201335.","journal-title":"Ann Rheum Dis"},{"key":"2249_CR17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10875-005-4091-5","volume":"25","author":"MV Jonsson","year":"2005","unstructured":"Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren\u2019s syndrome. J Clin Immunol. 2005;25:189\u2013201.","journal-title":"J Clin Immunol"},{"key":"2249_CR18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","volume":"62","author":"X Mariette","year":"2003","unstructured":"Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis. 2003;62:168\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2249_CR19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","volume":"52","author":"L Quartuccio","year":"2013","unstructured":"Quartuccio L, Salvin S, Fabris M, Maset M, Pontarini E, Isola M, et al. BLyS upregulation in Sjogren\u2019s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford). 2013 Feb;52(2):276\u201381.","journal-title":"Rheumatology (Oxford)"},{"key":"2249_CR20","doi-asserted-by":"crossref","unstructured":"Mielle J, Tison A, Cornec D, Le Pottier L, Daien C, Pers JO. B cells in Sj\u00f6gren\u2019s syndrome: from pathophysiology to therapeutic target. Rheumatology (Oxford). 2019;key332.","DOI":"10.1093\/rheumatology\/key332"},{"key":"2249_CR21","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/art.22458","volume":"56","author":"C Daridon","year":"2007","unstructured":"Daridon C, Devauchelle V, Hutin P, Le Berre R, Martins-Carvalho C, Bendaoud B, et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren\u2019s syndrome. Arthritis Rheum. 2007;56:1134\u201344.","journal-title":"Arthritis Rheum"},{"key":"2249_CR22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/path.1533","volume":"202","author":"F Lavie","year":"2004","unstructured":"Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol. 2004;202:496\u2013502.","journal-title":"J Pathol"},{"issue":"5","key":"2249_CR23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.smim.2006.04.005","volume":"18","author":"F Mackay","year":"2006","unstructured":"Mackay F, Leung H. The role of the BAFF\/APRIL system on T cell function. Semin Immunol. 2006;18(5):284\u20139.","journal-title":"Semin Immunol"},{"issue":"5","key":"2249_CR24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.smim.2006.06.002","volume":"18","author":"SL Kalled","year":"2006","unstructured":"Kalled SL. Impact of the BAFF\/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol. 2006;18(5):290\u20136.","journal-title":"Semin Immunol"},{"issue":"3","key":"2249_CR25","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","volume":"74","author":"X Mariette","year":"2015","unstructured":"Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy and safety of belimumab in primary Sj\u00f6gren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2249_CR26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","volume":"74","author":"S De Vita","year":"2015","unstructured":"De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, et al. Efficacy and safety of belimumab given for 12 months in primary Sj\u00f6gren\u2019s syndrome: the BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2249_CR27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","volume":"78","author":"T D\u00f6rner","year":"2019","unstructured":"D\u00f6rner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, et al. Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis. 2019 May;78(5):641\u20137.","journal-title":"Ann Rheum Dis"},{"key":"2249_CR28","doi-asserted-by":"crossref","first-page":"R170","DOI":"10.1186\/ar3493","volume":"13","author":"K Yoshimoto","year":"2011","unstructured":"Yoshimoto K, Tanaka M, Kojima M, Setoyama Y, Kameda H, Suzuki K, et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjogren\u2019s syndrome. Arthritis Res Ther. 2011;13:R170.","journal-title":"Arthritis Res Ther"},{"key":"2249_CR29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","volume":"324","author":"T Hirano","year":"1986","unstructured":"Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986;324:73\u20136.","journal-title":"Nature."},{"key":"2249_CR30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002960050070","volume":"18","author":"M Tishler","year":"1999","unstructured":"Tishler M, Yaron I, Shirazi I, Yossipov Y, Yaron M. Increased salivary interleukin-6 levels in patients with primary Sjogren\u2019s syndrome. Rheumatol Int. 1999;18:125\u20137.","journal-title":"Rheumatol Int"},{"key":"2249_CR31","first-page":"1089","volume":"24","author":"MM Grisius","year":"1997","unstructured":"Grisius MM, Bermudez DK, Fox PC. Salivary and serum interleukin 6 in primary Sjogren\u2019s syndrome. J Rheumatol. 1997;24:1089\u201391.","journal-title":"J Rheumatol"},{"key":"2249_CR32","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2249_CR33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.21591","volume":"64","author":"SC Shiboski","year":"2012","unstructured":"Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al. American College of Rheumatology classification criteria for Sj\u00f6gren\u2019s syndrome: a data-driven, expert consensus approach in the Sj\u00f6gren\u2019s International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012;64:475\u201387.","journal-title":"Arthritis Care Res"},{"key":"2249_CR34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3109\/s10165-004-0338-x","volume":"14","author":"T Fujibayashi","year":"2004","unstructured":"Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese criteria for Sj\u00f6gren\u2019s syndrome (1999): availability and validity. Mod Rheumatol. 2004;14:425\u201334.","journal-title":"Mod Rheumatol"},{"key":"2249_CR35","first-page":"429","volume":"44","author":"T Kawai","year":"1996","unstructured":"Kawai T, Itoh Y, Hirabayashi Y, Ichihara K, Igarashi S, Iwata S, et al. Establishment of reference intervals and physiological parameters for 13 serum proteins in healthy Japanese adults. Rinsho Byori. 1996;44:429\u201334.","journal-title":"Rinsho Byori"},{"key":"2249_CR36","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/acr.21610","volume":"64","author":"AS Malladi","year":"2012","unstructured":"Malladi AS, Sack KE, Shiboski SC, Shiboski CH, Baer AN, Banushree R, et al. Primary Sjogren\u2019s syndrome as a systemic disease: a study of participants enrolled in an international Sjogren\u2019s syndrome registry. Arthritis Care Res (Hoboken). 2012;64:911\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2249_CR37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","volume":"109","author":"J Groom","year":"2002","unstructured":"Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, et al. Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sjogren\u2019s syndrome. J Clin Invest. 2002;109:59\u201368.","journal-title":"J Clin Invest"},{"key":"2249_CR38","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/rheumatology\/40.6.656","volume":"40","author":"J Hulkkonen","year":"2001","unstructured":"Hulkkonen J, Pertovaara M, Antonen J, Pasternack A, Hurme M. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren\u2019s syndrome and correlate with the clinical manifestations of the disease. Rheumatology (Oxford). 2001;40:656\u201361.","journal-title":"Rheumatology (Oxford)"},{"key":"2249_CR39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/intimm\/dxh043","volume":"16","author":"B Huard","year":"2004","unstructured":"Huard B, Arlettaz L, Ambrose C, Kindler V, Mauri D, Roosnek E, et al. BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol. 2004;16:467\u201375.","journal-title":"Int Immunol"},{"key":"2249_CR40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-3083.2007.02049.x","volume":"67","author":"F Lavie","year":"2008","unstructured":"Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren\u2019s syndrome. Scand J Immunol. 2008;67:185\u201392.","journal-title":"Scand J Immunol"},{"issue":"20","key":"2249_CR41","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1182\/blood-2012-09-459289","volume":"121","author":"D Pinto","year":"2013","unstructured":"Pinto D, Montani E, Bolli M, Garavaglia G, Sallusto F, Lanzavecchia A, et al. A functional BCR in human IgA and IgM plasma cells. Blood. 2013;121(20):4110\u20134.","journal-title":"Blood."},{"issue":"1","key":"2249_CR42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","volume":"36","author":"E Samy","year":"2017","unstructured":"Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36(1):3\u201319.","journal-title":"Int Rev Immunol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02249-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:46:21Z","timestamp":1624409181000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02249-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2249"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02249-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]},"assertion":[{"value":"17 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committees of Keio University School of Medicine (#20100080, #20140335) and was conducted according to the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}